An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II.

MLA

Das, Sabyasachi, et al. “An Empowered, Clinically Viable Hematopoietic Stem Cell Gene Therapy for the Treatment of Multisystemic Mucopolysaccharidosis Type II.” Molecular Therapy : The Journal of the American Society of Gene Therapy, vol. 32, no. 3, Mar. 2024, pp. 619–36. EBSCOhost, https://doi.org/10.1016/j.ymthe.2024.01.034.

APA

Das, S., Rruga, F., Montepeloso, A., Dimartino, A., Spadini, S., Corre, G., Patel, J., Cavalca, E., Ferro, F., Gatti, A., Milazzo, R., Galy, A., Politi, L. S., Rizzardi, G. P., Vallanti, G., Poletti, V., & Biffi, A. (2024). An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II. Molecular Therapy : The Journal of the American Society of Gene Therapy, 32(3), 619–636. https://doi.org/10.1016/j.ymthe.2024.01.034

Chicago

Das, Sabyasachi, Fatlum Rruga, Annita Montepeloso, Agnese Dimartino, Silvia Spadini, Guillaume Corre, Janki Patel, et al. 2024. “An Empowered, Clinically Viable Hematopoietic Stem Cell Gene Therapy for the Treatment of Multisystemic Mucopolysaccharidosis Type II.” Molecular Therapy : The Journal of the American Society of Gene Therapy 32 (3): 619–36. doi:10.1016/j.ymthe.2024.01.034.